14/12/2004 -
Shiseido is to launch Adenogen, a new treatment for
hair loss.
Adenosine is one of the in vivo substances that exists in
the human body and the company’s extensive research on the
substance has shown that it directly affects the hair papillae,
a key part of the chemical reaction required to grow human hair.
Consequently this substance influences the production of FGF-7,
which is key to hair growth, and helps to speed up and encourage
the process.
Japan’s Corporate News reported that from
this finding Shiseido has developed a hair growth substance
called Adenosine, which has been given approval as an active
ingredient for medicated cosmetic products by the Japanese
Ministry of Health, Labour and Welfare.
The company says that it plans to launch
its own patented hair growth product for male pattern baldness
under the name Adenogen, using Adensosine as a key ingredient.
No launch date has as yet been confirmed for international
markets.
Shiseido has been carrying out pioneering
research into hair growth solutions from its Life Science
Research Centre in Yokohama. The research team has been making
advances towards a possible treatment for baldness by
researching TGF-beta2, a substance that is said to influence the
growth of hair cells.
The company already markets a number of
leading hair-growth treatments which are sold internationally.
They include its Intensive Hair Treatment Mask, which uses
ingredients that replicate hair cells to build up thinning hair.
Shiseido
is also active in the skin care segment and recently announced
the development of a new UV protection technology in conjunction
with BASF for high SPF treatments. |
